ALX Oncology To Host Investor Call And Webcast On October 3, 2023 To Share Interim Phase 2 ASPEN-06 Clinical Trial Results Of Evorpacept For The Treatment Of Advanced HER2-Positive Gastric Cancer
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology Holdings Inc. (NASDAQ:ALXO) will host an investor call and webcast on October 3, 2023, to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.
October 02, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ALX Oncology's announcement of the investor call and webcast to share interim Phase 2 ASPEN-06 clinical trial results could potentially impact its stock price.
The announcement of the investor call and webcast to share interim Phase 2 ASPEN-06 clinical trial results could potentially impact ALX Oncology's stock price. Investors will be closely watching the results, which could influence the company's stock price depending on whether the results meet, exceed, or fall short of expectations.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100